Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Long-term hepatitis C treatment does not reduce liver damage in large US study

This article was originally published in Scrip

Executive Summary

Long-term therapy with peginterferon does not reduce the rate of disease progression in patients with chronic hepatitis C who have not had an initial response to initial treatment with peginterferon and ribavirin, according to the results of a trial called HALT-C. The trial was published recently in the NEJM and was funded by the US National Institutes of Health(NIH), with additional support fromRoche.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts